IntelliPlex™ Lung Cancer Panel - cfDNA

The IntelliPlex™ Lung Cancer Panel comprises NSCLC driver genes' DNA mutations and RNA fusion variants detection for use with samples extracted from NSCLC formalin-fixed paraffin-embedded tissues (FFPET) or liquid biopsies such as plasma. The cfDNA panel is a qualitative molecular assay for the detection of 74 DNA mutation hotspots in the KRAS, NRAS, PIK3CA, BRAF, EGFR, HER2, MEK1 and AKT1 genes from plasma samples in a single well by using PlexBio's core πCode technology.

FEATURES

Detect 8 driver genes, 74 mutation hotspots in one well test
Highly sensitive (0.1~2.32%) to detect low levels of mutant DNA
Only ≥10ng DNA sample required
Time to results in <6 hours for 96 samples per run (sample preparation included)

DOWNLOAD FILE

Broad Target Coverage

Detectable 8 driver genes,
74 DNA mutations in one well

Low Sample Input

Only 10ng DNA sample extracted from plasma required

High Sensitivity

Detects low levels of mutant DNA with a high sensitivity

Quick Turnaround Time

Sample to results in <6 hours with automated reporting

Overview

Resources

Related Products

Overview

Most cases of lung cancer are sporadic, rather than hereditary, but several genes and even types of specific mutations are commonly seen in these sporadic cases. Due to the genetic diversity in lung cancers, a comprehensive and rapid test that access multiple genes' mutation profile simultaneously with a high level of accuracy, rather than individual gene testing is crucial and unmet need. Moreover, results are intended to assist clinicians in identifying patients who may benefit from available targeted treatments to achieve the personalized cancer management.

The IntelliPlex™Lung Cancer Panel- cfDNA is an in-vitro molecular test based on πCode™technology and PlexBio's instrument platform to identify 74 DNA mutations in KRAS, NRAS, PIK3CA, BRAF, EGFR, HER2, MEK1 and AKT1 genes in NSCLC. πCode™ technology enables the multi-mutations detection in single-well with DNA samples derived from plasma. The kit provides all necessary optimized reagents for the sensitive detection of low levels of mutant DNA in a background of wild-type genomic DNA by simultaneous PCR amplification of target mutations. The genetic status evaluation from these NSCLC driver genes can impact the selection of and the response to targeted therapies.

Principle of πCode Multiplexing

OUR RESOURCES

IFU

Datasheet

IntelliPlex™ Lung Cancer Panel - cfDNA

Type

IFU

Publish Date

2022.05.06

BACK TO LIST